奇正藏药(002287) - 2024 Q1 - 季度财报

Cash Flow - The total cash inflow from operating activities was CNY 218,276,103.92, a decrease of 15.7% compared to CNY 258,876,385.82 in the previous period[8]. - The net cash outflow from operating activities was CNY -191,328,489.83, compared to CNY -181,569,392.95 in the previous period, indicating a worsening cash flow situation[8]. - Cash inflow from investment activities totaled CNY 310,023,126.95, down from CNY 412,736,886.07 in the previous period, reflecting a decline of 25%[9]. - The net cash outflow from investment activities was CNY -276,882,207.67, compared to CNY -196,477,303.72 in the previous period, showing increased investment expenditures[9]. - Cash inflow from financing activities was CNY 439,200,000.00, significantly higher than CNY 100,000,000.00 in the previous period, indicating a strong increase in financing[9]. - The net cash flow from financing activities was CNY 435,845,246.86, compared to CNY 96,075,469.08 in the previous period, marking a substantial improvement[9]. - The ending cash and cash equivalents balance was CNY 356,202,070.72, compared to CNY 155,140,504.55 in the previous period, reflecting a significant increase[9]. - The net cash flow from operating activities was negative at CNY -191,328,489.83, slightly worse than CNY -181,569,392.95 in the same period last year, reflecting a decrease of 5.37%[26]. - Net cash flow from financing activities surged by 353.65% to ¥435,845,246.86, mainly from increased short-term borrowings[28]. - The cash flow from investment activities showed a decrease of 40.92% to -¥276,882,207.67, attributed to reduced cash received from redeemed financial products[28]. Revenue and Profit - The company reported a decrease in sales revenue from CNY 204,500,805.83 in the current period compared to CNY 233,203,887.28 in the previous period, a decline of approximately 12.3%[8]. - The company's operating revenue for Q1 2024 was CNY 365,098,756.48, representing a 23.37% increase compared to CNY 295,933,466.90 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 97,460,837.34, a 5.06% increase from CNY 92,763,157.33 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 56,028,485.72, showing a significant increase of 77.42% compared to CNY 31,579,085.46 in the previous year[26]. - The total profit for the period reached 113,292,210.72, an increase from 99,266,705.33 in the previous period, representing a growth of approximately 14.4%[35]. - The net profit attributable to the parent company was 97,460,837.34, compared to 92,763,157.33 in the previous period, reflecting an increase of about 5.5%[35]. - The company reported a total comprehensive income of 98,757,924.90, up from 92,017,954.47, indicating a growth of around 7.6%[35]. - The basic earnings per share for Q1 2024 was CNY 0.1838, up 4.91% from CNY 0.1752 in the previous year[26]. - The basic earnings per share for the current period was 0.1838, compared to 0.1752 in the previous period, showing an increase of approximately 3.3%[46]. - The diluted earnings per share also increased to CNY 0.1838, a rise of 4.97% compared to CNY 0.1751 year-on-year[26]. Assets and Liabilities - The total assets at the end of Q1 2024 reached CNY 6,765,391,354.56, marking a 7.41% increase from CNY 6,298,478,593.58 at the end of the previous year[26]. - The equity attributable to shareholders of the listed company was CNY 3,818,226,616.05, which is a 2.63% increase from CNY 3,720,328,772.46 at the end of the last year[26]. - The total liabilities rose to 2,896,084,887.25 from 2,528,334,499.93, which is an increase of approximately 14.5%[43]. - The company’s non-current assets totaled 3,110,749,140.88, slightly up from 3,104,111,394.14, reflecting a marginal increase of about 0.2%[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 20,787, with major shareholders holding significant stakes[3]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 9,446,950.75 during the reporting period[26]. - Other income increased by 162.63% to ¥9,808,790.23, primarily due to increased government subsidies[28]. Operational Efficiency - The weighted average return on equity was 2.59%, a slight decrease of 0.15% from 2.74% in the previous year[26]. - The company reported a decrease in credit impairment losses from -768,334.30 to -62,952.26, indicating improved credit quality[35]. - Accounts receivable increased by 218.30% to ¥241,286,912.21 due to sales collections not yet due[28]. - Prepayments rose by 312.26% to ¥28,465,596.46 primarily from increased advance payments to suppliers[28]. - Short-term borrowings increased by 97.47% to ¥891,596,091.68 mainly due to subsidiaries obtaining more short-term loans[28]. - Total operating costs increased by 13.76% to ¥299,888,820.46, with sales expenses rising to ¥169,679,519.01, a 18.77% increase[34]. - Investment income decreased by 80.19% to ¥10,285,742.77, reflecting reduced long-term equity investment gains[28]. Company Strategy - The company continues to focus on expanding its market presence and developing new products, although specific figures were not disclosed in the report[10]. - The company has not disclosed any new product developments or market expansion strategies in the provided content[36].